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CH
Droblems with occluder devices are rare. However, patients
hould be informed objectively about all potential risks.
efinitive surgical therapy has some perioperative impact
ut hardly any risk and, most important, excellent long-term
unctional outcome. Use of a flexible autologous pericardial
atch for defect closure guarantees an almost perfect phys-
ologic outcome without any reported risk of endocarditis.
here is essentially no mortality in the current era. Mini-
ally invasive techniques have evolved as very reliable and
ave become the clinical standard in experienced hands.
The most important result from this study is that defin-
tive surgical therapy can be performed safely with good
unctional outcome after complications of occluder place-
ent. This is even true in the presence of severe complica-
ions: for example, impairment of tricuspid valve function
r penetration of the device into the aortic root. Another
mportant finding is that a significant number of these
atients—one third after occluder placement and almost
alf of the patients in total—had some form of neurologic
nsult before definitive surgical closure of the defect. De-
pite this, the postoperative functional outcome was good.
his is clearly underlined by the fact that all patients fully
eturned to their preoperative routine work.
When evaluating the overall data, cardiologists and sur-
eons should agree on what has to be considered a compli-
ation and what complication rate with interventional ASD
losure should be considered as being acceptable. From the
atient’s perspective, any nonoptimal outcome, a residual
efect or additional complication, is unfavorable. Therefore,
he cardiologist and surgeon must strive for an optimal
esult regardless of the technique that is chosen. The attempt
t interventional ASD closure during routine cardiac cath-
terization with subsequent elective referral to surgical ther-
py was occurring in close to 10% of patients from our local
eries, but this should not be considered a complication.
his rate reflects the current practice of attempted interven-
ional closure, triggered by the patient=s interest, whenever
minimal chance of successful percutaneous treatment is
resent. In contradiction, any residual defect with imperfect
utcome or a severe complication, such as a neurologic
vent, should lead to surgical therapy. The incidence of
evere complications should be well below 1% in experi-
nced centers.
Interventional cardiologists are gaining experience with
ccluder placement. With the exception of the rare event of
artial embolizations, no real life-threatening complication
ill arise from failed attempts. Therefore, no surgical
tandby will be required. However, the conduct of interven-
ional approaches in close proximity to a surgical center
ith some cardiac surgical backup will always be preferable
n our opinion.
Are there any factors that will enable cardiologists andurgeons to foresee potential complications? There may be i
The Journal of Thoracicrelation between occluder size and the risk of complica-
ions.14 The size of the relatively stiff discs being impla
ay be one factor, and the direct distance to the aortic root
nd especially the presence of a sufficient rim at the superior
spect may be important when judging the risks of cardiac
erforation. However, as we evaluate our own data, the
atients requiring surgical therapy after occluder device
lacement are a rather heterogenic population. Equal num-
ers of patients having complications after device place-
ent have been referred over the years. Therefore, at
resent, no clear risk factors can be identified.
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iscussion
r Carl L. Backer (Chicago, Ill). My only conflict of interest is
hat I am a surgeon. The first question is, are there any cardiolo-
ists in the audience?
I want to congratulate Dr Walther and colleagues for focusing
ur attention, and ideally that of the interventional cardiologists,
n this relatively new indication for surgery in patients with
ongenital heart disease. That new indication is surgical ASD
losure after attempted device placement in the cardiac catheter-
zation laboratory.
and Cardiovascular Surgery ● Volume 134, Number 3 735
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CH
DOf concern, Dr Walther has reported a nearly 10% incidence
f surgical intervention for patients having complications of
evice placement. Within that group of patients, the most
oncerning are those requiring emergency surgery or those who
ad neurologic events. Two patients required an emergency
peration and 7 patients had serious neurologic issues. One of
hose patients, in fact, died of sepsis after surgical device
emoval and ASD closure. Dr Walther appropriately compares
hese results with a 0% mortality with negligible morbidity in a
eries of surgical ASD closures totaling nearly 1000 patients.
At Children’s Memorial Hospital in Chicago, our series of
urgical ASD closures is now 237 patients since 1990 with no
ortality. Since 1997, of 143 patients undergoing attempted de-
ice closure, there were a total of 11 patients who underwent an
nterventional catheterization procedure and then were referred for
urgery. Two patients were referred because the defect was too
arge and there was no room for device placement. Seven patients
ad attempted closure in the catheterization laboratory with the
evice, but were referred for elective surgery because the device
losure was not successful. Two patients had attempted device
losure and required emergency operation when the device embo-
ized to the mitral valve and to the left atrium. Our incidence of
equirement for surgical intervention of 7.7% is very similar to
ours.
I have 3 questions and a comment. First, should surgical
ackup always be available on site when these interventional cases
re done?
Dr Walther. Thank you very much for that question. I person-
lly think that interventional procedures should only be done in a
enter where there is a cardiac surgeon in-house. However, the
ardiologists will probably go on and implant the devices in
atients as much as they want because no one can stop them. They
robably will not accept it if they are told they can only do that if
backup is available.
Dr Backer. My second question relates to the patients who
ave an attempted but unsuccessful transcatheter closure with the
evice and are hence exposed to general anesthesia, potential
roblems of femoral vessel cannulation, possible device emobo-
ization, et cetera. What do you think is an appropriate incidence of
nsuccessful device placement during this procedure? To me, 7%
o 10% seems to be rather high.
Dr Walther. You are right. The procedure is getting clinically
outine now. I think it should have a failure rate of less than 1%.
do not consider it a device failure when the patient is taken to the
atheterization laboratory, the defect is found to be too large, and
he cardiologists choose to send the patient to us for elective
urgical repair. Failures are cases in which there is an embolization
f the device or there is a marked position of the device wherein
he tricuspid valve is impaired, for example. I think such compli-
ations should be below 1%.
Dr Backer. Finally, can we somehow decrease the number of
atients subjected to the expense and risk of device closure without
successful result by establishing better patient selection criteria?
Dr Walther. That is a very important question, but a very
ifficult one. The cardiologist is the gatekeeper, and he or she will
nly send us those patients whose ASDs cannot be closed inter-
entionally. s
36 The Journal of Thoracic and Cardiovascular Surgery ● SepteOne of the goals in our group is to bring this issue to the
ttention of more patients. It would be very good to have a joint
iscussion to set up syndication between cardiologists and sur-
eons after the diagnosis is made. However, we are not able to get
he patients unless the cardiologist sends them.
Dr Backer. I had a comment to make, but I will save that
ecause of the number of discussers yet to come.
I will say, though, that surgical ASD closure is an extraordi-
arily safe and efficacious operation with minimal morbidity that
hould not be forgotten but actually considered the benchmark
hen considering alternative methods for ASD closure.
Dr Christopher Knott-Craig (Oklahoma City, Okla). Was
here a common denominator in the patients who required surgery
fter ASD device closure? For example, were the sizes of the
evices that were placed unusually large?
Dr Walther. It is difficult to say because we have different
eferrals from different areas. It is not an all-comers series. But
asically, so far as I understand, cardiologists are going up with the
izes. Five to 8 years ago they did not use a 38-mm Amplatzer
evice; the upper limit was 30 mm in the late 1990s. Now they use
lmost 40-mm devices. Therefore, I think it is a change in indica-
ion for them.
Dr Giovanni Stellin (Padova, Italy). I have just reviewed a
anuscript that will be published in the Italian journal, reporting
n a case of late embolization after device ASD closure. The
evice embolized in the pulmonary artery and that was discovered
months after the implantation. I was wondering whether, in your
xperience, you have found any late embolizations? This has
lready been reported as a possibility.
Dr Walther. There was one such case, but it was after a few
eeks; it was not that late.
Dr Stellin. That was 6 months later.
Dr Walther. They are basically talking about these patients to
ther surgeons. We have discussed this situation in the German
ongenital surgical group. Everyone has seen a few such cases, I
hink. We need to set up a multicenter evaluation to really bring
ogether all data from different centers.
Dr Backer. I just want to ask, with a raise of hands, how many
eople have taken Amplatzer devices out of the atrium or femoral
essels or elsewhere? [Show of hands.] That is nearly everyone!
et me ask in a different way: Are there any congenital heart
urgeons here who have not removed an Amplatzer device some-
ime in their career? [Show of hands.] Only three hands go up!
Dr Charles D. Fraser, Jr (Houston, Tex). I would like to make
couple of comments.
The first problem, of course, is the issue that Dr Backer ob-
erved in his opening sentence. There are no pediatric cardiologists
ere. To really make an impact on these various issues, which are
ontinuing to evolve, we are going to have to make sure that these
ata are shared in a forum where a truly meaningful discussion can
o on about what is the best therapy for closing holes in hearts.
Might you reconsider what a failure is? Of course, the failure to
patient is when you are told you have an ASD and you come to
he hospital to get it closed and you go home still having an ASD.
In our institution, what happens frequently is that the patient
omes to the hospital, undergoes a general anesthetic, possibly a
ransesophageal echocardiogram, perhaps an intravascular ultra-
ound, and then is told that the defect is too large and is sent home.
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Walther et al Surgery for Congenital Heart Diseasehe patient gets charged, the insurance company gets charged, and
hen the patient comes back for surgical closure. That, to me, is a
ailure. I think that should be considered in the statistics. It is
ertainly a very expensive mode of therapy. Might you look at
our data a little bit differently in that regard?
Dr Walther. Basically, you are right. That if the patient leaves
he hospital with a residual ASD, that is a failure. But we were
ooking at severe complications, for instance, if there are no
ymptoms in such a patient. It is a question of definition.
Dr Pedro del Nido (Boston, Mass). The device industry is
hat I would call disruptive technology. As such, it is always
orse than the standard therapy for a period of time. Eventually,
owever, the technology gets better. All you have to do is look at
omputers to have a good example; a lot of the original equipment
hat we had years ago, now we would not even look at. I do not
now that it is a good idea to just dismiss the problems with
evices as complications of a bad system.
The cardiologists are very much aware of these problems.
ortic erosion has been described, but it has been primarily de-
cribed for the larger devices, and interventionalists are changing
heir practice. Do you have an idea what the size was in the devices
mplanted? Did you actually measure the size of your devices or
et the procedure notes to determine the size of the devices that
ere put in?
Dr Walther. Unfortunately, I do not have all those data be-
ause these were natural referrals and we do not get the procedure
eports from all of those.
Dr del Nido. It is important to try to learn from these cases. In
he interventional world, such cases are coming out now, although k
The Journal of Thoracicome of them have not made it to print yet. The larger devices, and
nything over about 36 mm is considered the larger size, are the
nes that are causing the complications. This problem occurs with
uch less frequency with the smaller devices. The importance of
his is that if you have a large cohort of patients who are out there
ith larger devices in place, then close follow-up is absolutely
mperative. There have been instances of late left atrial erosion,
ortic root erosion, and mitral valve erosion, especially the cases in
hich there was no rim and the device was deliberately oversized
o capture the rim of the aorta.
Dr Backer. Can I just make a quick comment? I was going to
dd this to my discussion.
I agree with you, Dr del Nido, that the cardiologists are aware
f this problem. But I disagree with the way they interpret the data.
his article that I am quoting is from Catheterization and Cardio-
ascular Interventions (2004;63:496-502), and it is the Amplatzer
tudy group. They discuss erosion of Amplatzer septal occluder
evices and their recommendations are as follows: “Patients with
eficient aortic rim and/or superior rim may be at higher risk
or device erosion. Oversized Amplatzer device may increase the
isk of erosion. The defect should not be overstretched during
alloon sizing. Patients with small pericardial effusion at 24 hours
hould have closer follow-up.”
Nowhere in that conclusion does it say that thought should be
iven to sending the patient to surgery if an oversized device is
eeded or if there is lack of a superior rim or of an aortic rim.
The cardiologists are not looking to the surgeons to treat these
atients; they are looking for ways of tweaking their system to
eep the patients within the device closure strategy.
and Cardiovascular Surgery ● Volume 134, Number 3 737
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